Iberdomide + dexamethasone in R/R multiple myeloma Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, presents the results of a study evaluating iberdomide, a cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone in patients with triple-class refractory multiple myeloma or in patients who have been exposed to an […]

Read More

Our Ongoing Commitment to Multiple Myeloma Patients Globally, about 176K people were diagnosed with #MultipleMyeloma (MM) in 2021. Despite current treatment options, high relapse rates require innovative approaches. We’re working to evolve research around #BCMA, a promising target in MM. For more: https://www.mmwayforward.com/ #EBMT22

Read More